Whittier Trust Co. of Nevada Inc. Sells 185 Shares of Illumina, Inc. (NASDAQ:ILMN)

Posted by Defense World Staff on Apr 7th, 2023

Whittier Trust Co. of Nevada Inc. decreased its stake in shares of Illumina, Inc. (NASDAQ:ILMN – Get Rating) by 28.1% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 474 shares of the life sciences company’s stock after selling 185 shares during the period. Whittier Trust Co. of Nevada Inc.’s holdings in Illumina were worth $96,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of ILMN. Financial Consulate Inc. lifted its position in Illumina by 3.5% during the third quarter. Financial Consulate Inc. now owns 1,617 shares of the life sciences company’s stock valued at $309,000 after purchasing an additional 54 shares in the last quarter. Geneos Wealth Management Inc. lifted its holdings in Illumina by 28.6% during the first quarter. Geneos Wealth Management Inc. now owns 270 shares of the life sciences company’s stock worth $94,000 after buying an additional 60 shares during the period. Massmutual Trust Co. FSB ADV lifted its holdings in shares of Illumina by 50.0% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 183 shares of the life sciences company’s stock valued at $35,000 after purchasing an additional 61 shares during the last quarter. Ronald Blue Trust Inc. increased its position in shares of Illumina by 25.3% in the 4th quarter. Ronald Blue Trust Inc. now owns 312 shares of the life sciences company’s stock valued at $59,000 after acquiring an additional 63 shares during the period. Finally, Crossmark Global Holdings Inc. grew its position in Illumina by 0.9% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 7,032 shares of the life sciences company’s stock worth $1,341,000 after purchasing an additional 64 shares during the period. 87.97% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently weighed in on ILMN. Citigroup lowered shares of Illumina from a “neutral” rating to a “sell” rating and decreased their price target for the company from $200.00 to $180.00 in a research note on Monday, December 12th. Bank of America boosted their price target on shares of Illumina from $210.00 to $230.00 in a research report on Wednesday, February 8th. Argus lowered shares of Illumina from a “buy” rating to a “hold” rating in a research note on Wednesday, January 25th. They noted that the move was a valuation call. Piper Sandler reissued an “overweight” rating and set a $290.00 price objective on shares of Illumina in a research note on Wednesday, February 8th. Finally, Royal Bank of Canada cut their target price on shares of Illumina from $303.00 to $300.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 15th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $249.40.

Insiders Place Their Bets

In other news, SVP Aimee L. Hoyt sold 3,917 shares of the company’s stock in a transaction that occurred on Wednesday, March 1st. The stock was sold at an average price of $199.06, for a total transaction of $779,718.02. Following the transaction, the senior vice president now directly owns 2,881 shares of the company’s stock, valued at $573,491.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, SVP Aimee L. Hoyt sold 3,917 shares of the stock in a transaction on Wednesday, March 1st. The stock was sold at an average price of $199.06, for a total value of $779,718.02. Following the completion of the sale, the senior vice president now directly owns 2,881 shares of the company’s stock, valued at approximately $573,491.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Susan H. Tousi sold 500 shares of the stock in a transaction on Monday, February 6th. The shares were sold at an average price of $211.57, for a total value of $105,785.00. Following the completion of the sale, the senior vice president now directly owns 38,276 shares of the company’s stock, valued at $8,098,053.32. The disclosure for this sale can be found here. In the last three months, insiders have sold 10,686 shares of company stock worth $2,153,547. Corporate insiders own 0.13% of the company’s stock.

Illumina Stock Performance

NASDAQ:ILMN opened at $229.99 on Friday. The stock has a market cap of $36.34 billion, a P/E ratio of -8.21, a price-to-earnings-growth ratio of 8.39 and a beta of 1.18. The company has a current ratio of 1.28, a quick ratio of 1.08 and a debt-to-equity ratio of 0.23. The stock’s 50-day moving average is $214.02 and its 200-day moving average is $210.74. Illumina, Inc. has a 1-year low of $173.45 and a 1-year high of $370.54.

Illumina (NASDAQ:ILMN – Get Rating) last released its quarterly earnings results on Tuesday, February 7th. The life sciences company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.25 by ($0.11). Illumina had a positive return on equity of 3.79% and a negative net margin of 96.12%. The firm had revenue of $1.08 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter last year, the firm posted $0.75 earnings per share. The business’s revenue for the quarter was down 9.2% on a year-over-year basis. Equities research analysts anticipate that Illumina, Inc. will post 1.41 earnings per share for the current year.

Illumina Company Profile

(Get Rating)

Illumina, Inc engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions.

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.